BG40654A3 - Method for preparing cycloalkyltriazoles - Google Patents

Method for preparing cycloalkyltriazoles

Info

Publication number
BG40654A3
BG40654A3 BG7943291A BG4329179A BG40654A3 BG 40654 A3 BG40654 A3 BG 40654A3 BG 7943291 A BG7943291 A BG 7943291A BG 4329179 A BG4329179 A BG 4329179A BG 40654 A3 BG40654 A3 BG 40654A3
Authority
BG
Bulgaria
Prior art keywords
cycloalkyltriazoles
preparing
preparing cycloalkyltriazoles
Prior art date
Application number
BG7943291A
Other languages
English (en)
Inventor
Silvestrini
Baiocchi
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. Spa,It
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. Spa,It filed Critical Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. Spa,It
Publication of BG40654A3 publication Critical patent/BG40654A3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG7943291A 1978-04-18 1979-04-18 Method for preparing cycloalkyltriazoles BG40654A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22421/78A IT1094076B (it) 1978-04-18 1978-04-18 Cicloalchiltriazoli

Publications (1)

Publication Number Publication Date
BG40654A3 true BG40654A3 (en) 1987-01-15

Family

ID=11196066

Family Applications (2)

Application Number Title Priority Date Filing Date
BG7943291A BG40654A3 (en) 1978-04-18 1979-04-18 Method for preparing cycloalkyltriazoles
BG98586A BG61367B2 (bg) 1978-04-18 1994-02-25 Циклоалкилтриазоли

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG98586A BG61367B2 (bg) 1978-04-18 1994-02-25 Циклоалкилтриазоли

Country Status (22)

Country Link
US (2) US4252721A (hu)
JP (1) JPS5817757B2 (hu)
AT (1) AT374477B (hu)
AU (1) AU520788B2 (hu)
BG (2) BG40654A3 (hu)
CA (1) CA1104567A (hu)
CH (1) CH639847A5 (hu)
DE (1) DE2915318A1 (hu)
DK (1) DK148480C (hu)
FI (1) FI66378C (hu)
FR (1) FR2423221A1 (hu)
GB (1) GB2020269B (hu)
HU (1) HU179917B (hu)
IE (1) IE47965B1 (hu)
IL (1) IL56926A (hu)
IT (1) IT1094076B (hu)
NL (1) NL186635C (hu)
PL (1) PL116103B1 (hu)
PT (1) PT69502A (hu)
SE (1) SE437663B (hu)
SU (1) SU852174A3 (hu)
YU (1) YU41338B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US6187774B1 (en) 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
WO2003004058A1 (en) * 2001-07-02 2003-01-16 Santen Pharmaceutical Co., Ltd. OPTIC NERVE PROTECTING AGENTS CONTAINING α1 RECEPTOR BLOCKER AS THE ACTIVE INGREDIENT
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CA2753318A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
TW200811101A (en) * 2006-07-14 2008-03-01 Ranbaxy Lab Ltd Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
SG11202104094YA (en) 2018-10-26 2021-05-28 Ocuphire Pharma Inc Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
JPS5070389A (hu) * 1973-10-30 1975-06-11

Also Published As

Publication number Publication date
FR2423221B1 (hu) 1983-03-18
GB2020269B (en) 1982-06-03
DE2915318C2 (hu) 1990-12-13
NL186635B (nl) 1990-08-16
IT7822421A0 (it) 1978-04-18
IE790646L (en) 1979-10-18
IL56926A (en) 1983-09-30
HU179917B (en) 1983-01-28
SU852174A3 (ru) 1981-07-30
AU520788B2 (en) 1982-02-25
IE47965B1 (en) 1984-08-08
NL186635C (nl) 1991-01-16
PL116103B1 (en) 1981-05-30
ATA292479A (de) 1983-09-15
JPS54157576A (en) 1979-12-12
DK156779A (da) 1979-10-19
AT374477B (de) 1984-04-25
DE2915318A1 (de) 1979-10-31
GB2020269A (en) 1979-11-14
FI66378C (fi) 1984-10-10
SE7903327L (sv) 1979-10-19
JPS5817757B2 (ja) 1983-04-09
YU41338B (en) 1987-02-28
FR2423221A1 (fr) 1979-11-16
DK148480B (da) 1985-07-15
FI66378B (fi) 1984-06-29
IL56926A0 (en) 1979-05-31
PT69502A (en) 1979-05-01
CA1104567A (en) 1981-07-07
NL7902489A (nl) 1979-10-22
CH639847A5 (it) 1983-12-15
FI791217A (fi) 1979-10-19
US4252721A (en) 1981-02-24
PL214969A1 (hu) 1980-03-10
AU4583279A (en) 1979-10-25
YU86279A (en) 1983-12-31
DK148480C (da) 1985-12-16
SE437663B (sv) 1985-03-11
BG61367B2 (bg) 1997-06-30
IT1094076B (it) 1985-07-26
US4307095A (en) 1981-12-22

Similar Documents

Publication Publication Date Title
BG40654A3 (en) Method for preparing cycloalkyltriazoles
BG38164A3 (en) Method for preparing n- substanced- 4- piperidanoamides
YU42191B (en) Process for preparing 2-chloro-6-nitroanilines
BG40481A3 (en) Method for preparing phenetanolamines
GB2018816B (en) Process for preparing hexamethyltetrahydronaphthalenes
BG31492A3 (en) Method for obtaining phenetanolamines
PT70314A (en) Process for preparing substituted 1-thia-3-aza-4-ones
BG35033A3 (en) Method for preparing o- metalyloxyphenol
GB2034701B (en) Process for preparing 2-chlorosulphinylazetidinones
GB2019835B (en) Process for preparing n-carbamoyl-d-thienylglycines
DE2961058D1 (en) Process for preparing alpha-chloro-n-monoalkyl-acetoacetamides
DE2960047D1 (en) Process for preparing 2-oximinophenylacetonitrile
YU41093B (en) Process for preparing 6-deoxy-5hydroxy-tetracycline
GB2013180B (en) Process for preparing n ethylethylenediamine
BG40315A3 (en) Method for preparing auronic derivatives
YU40533B (en) Process for preparing 2-bromoergosinine
DE2964629D1 (en) Process for preparing 3-amino-5-t-butylisoxazole
DE2963897D1 (en) Process for preparing sodium-m-nitrobenzenesulfonate
PT67655B (en) Method for preparing cyano-alquyl-guanidines
PH15975A (en) Process for preparing cis-bicyclooctylamines
PT69287A (en) Process for preparing benzocycloheptapyrans
GB2025414B (en) Process for preparing cis-bicyclooctylamines
BG40479A3 (en) Method for preparing phenylethyr compounds
BG29479A1 (en) Method for 9- bensylharmine obtaining
ZM8279A1 (en) Process for preparing 2-chlorosulfinylazetidinones